6 completed, 3 terminated, 1 enrolling by invitation, 1 recruiting. 12 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 6, Terminated 3, Enrolling by invitation 1, Recruiting 1, Unknown 1 |
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
Follow Pulmonary Emphysema: new trials by email Literature Review of Pulmonary Emphysema trials Research Report on Pulmonary Emphysema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) Alpha-1 15%, Liquid Alpha1-PI - Alpha 1 Antitrypsin Deficiency | Phase 3 | Recruiting | Grifols Therapeutics LLC | 40 | 2026-05-05 | 2026-10-26 |
| Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency Alpha-1 MP - Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | Phase 3 | Enrolling by invitation | Grifols Therapeutics LLC | 290 | 2016-07-01 | 2026-06-23 |
| Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP - Pulmonary Emphysema in Alpha-1 PI Deficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 345 | 2014-04-01 | 2026-10-01 |
| Post-hospitalisation Nutritional Support and Gait Speed in COPD Food fortification, Oral Nutritional Supplements - Pulmonary Disease, Chronic Obstructive, Respiratory Tract Diseases | Phase 3 | Terminated | Royal Brompton & Harefield NHS Foundation Trust | 22 | 2014-01-01 | 2015-11-02 |
| The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients Endobronchial valve - Pulmonary Emphysema | Phase 3 | Completed | Asan Medical Center | 43 | 2013-03-01 | 2017-06-27 |
| Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE) Treatment plus Optimal Medical Therapy, Optimal Medical Therapy - Pulmonary Emphysema | Phase 3 | Terminated | Aeris Therapeutics | 300 | 2012-06-01 | 2013-11-14 |
| A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema AeriSeal System - Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease(COPD) | Phase 2 / Phase 3 | Terminated | Aeris Therapeutics | 18 | 2011-03-01 | 2013-11-14 |
| AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema AeriSeal System - Pulmonary Emphysema, COPD | Phase 2 / Phase 3 | Completed | Aeris Therapeutics | 20 | 2010-08-01 | 2011-10-21 |
| Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study IBV Implantation - Pulmonary Emphysema | Phase 2 / Phase 3 | Unknown | Heidelberg University | 20 | 2009-09-01 | 2011-04-27 |
| Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Kamada-API - Alpha 1-Antitrypsin Deficiency | Phase 2 / Phase 3 | Completed | Kamada, Ltd. | 50 | 2007-03-01 | 2007-10-17 |
| The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency alpha-1 proteinase inhibitor (human) - Alpha 1-Antitrypsin Deficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 38 | 2006-06-01 | 2014-08-19 |
| Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Alpha-1 MP, alpha-1 proteinase inhibitor (human) - Alpha 1-Antitrypsin Deficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 24 | 2006-05-01 | 2014-09-09 |
Pulmonary Disease, Chronic Obstructive (7) · Emphysema (6) · alpha 1-Antitrypsin Deficiency (6) · Respiratory Tract Diseases (5) · Lung Diseases (4) · Pathologic Processes (3) · Lung Diseases, Obstructive (2) · Respiratory Aspiration (2) · Bronchitis, Chronic (1) · Genetic Diseases, Inborn (1) · Subcutaneous Emphysema (1)
Chronic Disease (12) · Disease Attributes (12) · Pathological Conditions, Signs and Symptoms (12) · Lung Diseases, Obstructive (10) · Pathologic Processes (9) · Lung Diseases (8) · Respiratory Tract Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Digestive System Diseases (6) · Liver Diseases (6) · Emphysema (5) · Genetic Diseases, Inborn (5) · Pulmonary Disease, Chronic Obstructive (5) · Subcutaneous Emphysema (5) · Respiration Disorders (2)
Mp alpha1 receptor (3) · alpha 1-Antitrypsin (2) · 15-keto-17-phenyl-18,19,20-trinorprostaglandin F2 alpha-1-isopropyl ester (1) · Dietary Supplements (1) · Injections (1) · Sodium Chloride (1) · Therapeutics (1)
Grifols Therapeutics LLC (5) · Aeris Therapeutics (3) · Asan Medical Center (1) · Heidelberg University (1) · Kamada, Ltd. (1) · Royal Brompton & Harefield NHS Foundation Trust (1)
United States (7) · Denmark (3) · France (3) · Germany (3) · Israel (3) · Poland (3) · Spain (3) · Sweden (3) · Australia (2) · Canada (2) · Estonia (2) · Finland (2) · Moldova (2) · Netherlands (2) · New Zealand (2)
Kim Hanna, MSc (2) · Felix JF Herth, MD (1) · Robert A Sandhaus, M.D. (1) · Sei Won Lee, MD (1) · William Man, PhD FRCP (1)
PMID 20920295, PMID 22374920, PMID 22459779, PMID 23822603, PMID 25727857, PMID 25837041, PMID 26251590
2025 (1)